Article

Biomarker Guided Chemotherapy and Immunotherapy Response in Asian Triple-Negative Breast Cancer: A Systematic Review

2026-06-25

Abstract excerpt

Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by the absence of ER, PR, and HER2 expression, with limited therapeutic targets and poor prognosis. Chemotherapy remains the cornerstone of treatment; however, response variability highlights the need for predictive biomarkers. This systematic review aims to evaluate biomarker-guided chemotherapy and immunotherapy responses in Asian TNBC p...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e08c85cb-f177-5ebb-bd6c-4fd9670fcf2e
DOI: 10.12688/f1000research.181789.1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Biomarker Guided Chemotherapy and Immunotherapy Response in Asian Triple-Negative Breast Cancer: A Systematic ReviewDOI 10.12688/f1000research.181789.1Read

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategiesSemantic proximity Read

Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic AdvancementsSemantic proximity Read

New Biomarkers and Treatment Advances in Triple-Negative Breast CancerSemantic proximity Read

Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic review and meta-analysis.Semantic proximity Read

Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: A systematic review and meta-analysisSemantic proximity Read

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapiesSemantic proximity Read

Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review)Semantic proximity Read

The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.Semantic proximity Read

Emerging Protein Targets in Triple Negative Breast Cancer: Beyond Conventional TherapySemantic proximity Read

BRCA1/2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisSemantic proximity Read

Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast CancerSemantic proximity Read

Biology and Management of Patients With Triple-Negative Breast CancerSemantic proximity Read